Senti Biosciences’ Post

Today we announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf CAR-NK investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). Learn more: https://bit.ly/3yhWWZW  #celltherapy #AML #CARNK

  • No alternative text description for this image
Marcela Guzmán Ayala, PhD

Developing impactful therapies against cancer and infectious diseases

6mo

Very exciting news! Congratulations to the present and past members of the team involved in the development of this promessing therapy.

Like
Reply
Robin Taylor

Chief Commercial Officer, Agenus

6mo

Congratulations to the Senti team on this important milestone!

Like
Reply
Maura Gavaghan

Biotech Communications | Corporate Communications and Public Relations | Translating science into compelling stories

6mo

Congrats, Senti team!!!

Like
Reply
Ginny Spadoni

Medical and Scientific Affairs Leader

6mo

Congratulations!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics